Recommended Treatment for Candidemia
For candidemia, initiate an echinocandin (caspofungin, micafungin, or anidulafungin) as first-line therapy, remove central venous catheters within 48-72 hours when feasible, obtain daily blood cultures until three consecutive negatives, and continue treatment for 14 days after bloodstream clearance and symptom resolution 1, 2.
First-Line Antifungal Therapy
Echinocandins (Preferred)
The 2025 global guideline and 2016 IDSA guidelines both strongly recommend echinocandins as first-line therapy 1, 2. This class demonstrates superiority over fluconazole, particularly in:
- Critically ill patients
- Those with septic shock
- Patients with recent azole exposure
- Settings with high rates of azole-resistant species (C. glabrata, C. krusei)
Dosing regimens:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily 2
Alternative Agents
Fluconazole (800 mg loading dose, then 400 mg daily) is acceptable only for:
- Non-critically ill patients
- No prior azole exposure
- Confirmed azole-susceptible isolates
- Step-down therapy after clinical stabilization 1, 2
Lipid formulation amphotericin B (3-5 mg/kg daily) is reserved for:
- Intolerance to echinocandins
- Suspected echinocandin resistance
- CNS involvement (where it's strongly recommended, usually combined with flucytosine) 1, 2
Critical Management Components
Source Control
Remove central venous catheters within 48-72 hours when the catheter is the presumed source and removal can be performed safely 1. This is a strong recommendation that significantly impacts outcomes. The 2025 guideline emphasizes "as early as possible" rather than individualizing this decision 1.
Monitoring Requirements
Daily blood cultures until three consecutive negative results 1. If blood cultures remain positive on day 5, repeat search for intravascular or uncontrolled sources 1.
Ophthalmologic examination within the first week after diagnosis to exclude endophthalmitis 2. For ocular involvement:
- Use fluconazole or voriconazole for azole-susceptible species
- Avoid echinocandins due to poor posterior chamber penetration 1
- Consider intravitreal therapy or vitrectomy for endophthalmitis 1
Treatment Duration
14 days after documented bloodstream clearance AND resolution of symptoms 1, 2. This applies to uncomplicated candidemia without metastatic complications.
Special Populations
Neutropenic Patients
- Echinocandin remains first-line 2
- Lipid formulation amphotericin B is an alternative
- Fluconazole only if not critically ill and no prior azole exposure
- Continue therapy until neutropenia resolves 2
Patients with Septic Shock
Echinocandins are mandatory given their demonstrated superiority over fluconazole in this population 1.
Step-Down Therapy
Transition from echinocandin to fluconazole after 5-7 days is appropriate when:
- Patient is clinically stable
- Repeat blood cultures are negative
- Isolate is fluconazole-susceptible
- No evidence of metastatic complications 2
Common Pitfalls to Avoid
- Do not use fluconazole empirically in critically ill patients - echinocandins are superior 1
- Do not use echinocandins for endophthalmitis - poor ocular penetration 1
- Do not delay catheter removal - early removal (within 48-72 hours) improves outcomes 1
- Do not stop therapy at 14 days total - the 14-day clock starts AFTER bloodstream clearance 1, 2
- Do not skip ophthalmologic examination - endophthalmitis requires different management 2
Emerging Resistance Considerations
The 2025 guideline emphasizes reviewing treatment decisions based on local epidemiology and susceptibility testing results 1. Rising resistance in C. parapsilosis to echinocandins and C. auris emergence require ongoing surveillance and susceptibility-guided therapy 3, 4.